Haleon vs Universe Pharmaceuticals
Universe Pharmaceuticals is the larger business, with $17.86bn of revenue in fiscal 2025 against $14.55bn for Haleon (1.2 times as much). Haleon grew faster (1.3% against -22.4%). Haleon kept more of each dollar of sales as profit: a net margin of 15.1% against -20.6%. Universe Pharmaceuticals carries less debt relative to equity (16.5% against 52.4%).
| Latest fiscal year | HaleonHLN, 2025 | Universe PharmaceuticalsUPC, 2025 |
|---|---|---|
| Revenue | $14.55bn | $17.86bn |
| Revenue growth | 1.3% | -22.4% |
| Net income | $2.20bn | −$3.67bn |
| Operating margin | 21.9% | -16.3% |
| Net margin | 15.1% | -20.6% |
| Return on equity | 10.4% | -7.2% |
| Free cash flow | $3.05bn | −$5.32bn |
| Cash | $1.78bn | $33.59bn |
| Total debt | $11.58bn | $9.26bn |
| Debt to equity | 52.4% | 16.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $39.59bn | $844,444 |
| Price vs our value range | Above our value range | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |